Adeno-associated Virus Vector class drugs

1 result

Luxturna (voretigene neparvovec-rzyl)

(voretigene neparvovec-rzyl)
Spark Therapeutics, Inc.
Usage: LUXTURNA (voretigene neparvovec-rzyl) is a gene therapy indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, provided they have viable retinal cells as assessed by their physician.